Stocktoria
Roivant Sciences Ltd. ROIV
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-12-03
Chart by TradingView
1/9
Piotroski F — financial health
16.14
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Valuation · market cap as of 2026-06-29
Market cap$24.5B
P / B5.4×
Financials & ratios (annual, from 10-K)
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $8.3M | $29.1M | $32.7M | $31.5M | $55.3M |
| Operating income | -$515.1M | -$1.0B | $4.5B | -$906.8M | -$1.4B |
| Net income | -$299.8M | -$172.0M | $4.3B | -$1.0B | -$845.3M |
| Operating cash flow | -$750.3M | -$839.5M | -$765.3M | -$843.4M | -$677.7M |
| Free cash flow | -$758.6M | -$844.0M | -$766.6M | -$856.1M | -$695.2M |
| Total assets | $5.7B | $5.4B | $7.2B | $2.4B | $2.6B |
| Total liabilities | $416.3M | $249.7M | $774.0M | $782.0M | $523.7M |
| Shareholders' equity | $4.5B | $5.2B | $6.4B | $1.6B | $2.0B |
| Ratios | |||||
| Operating margin | -6235.7% | -3453.3% | 13746.9% | -2875.9% | -2444.8% |
| Net margin | -3629.2% | -592.0% | 13294.2% | -3200.2% | -1528.9% |
| FCF margin | -9183.5% | -2905.2% | -2343.6% | -2715.1% | -1257.4% |
| Return on assets | -5.3% | -3.2% | 60.2% | -42.2% | -32.7% |
| Return on equity | -6.6% | -3.3% | 67.4% | -62.8% | -41.5% |
| Debt / equity | — | — | 0.07× | 0.23× | 0.10× |
| Current ratio | 18.37 | 33.47 | 25.24 | 6.60 | 11.64 |
| Revenue growth | -71.6% | -11.2% | 3.8% | -43.0% | 132.3% |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 16.14 (safe)
- Working capital / assets 0.856
- Retained earnings / assets -0.088
- EBIT / assets -0.09
- Equity / liabilities 10.876
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001635088 · as of 2026-03-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.